Determination of an improved sirolimus (Rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilyphocyte serum and donor-specific bone marrow

Transplantation

Volumn 65, Issue 4, 1998, Pages 473-479

  Hale, Douglas A ^a   Gottschalk, Rita ^a   Maki, Takashi ^a   Monaco, Anthony P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT; SKIN TRANSPLANTATION;

ANIMALS; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED DBA; MICE, INBRED STRAINS; POLYENES; RABBITS; SIROLIMUS; SKIN TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032570744     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199802270-00004     Document Type: Article

References (38)

1. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55: 48.
2. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 609.
3. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting [Letter; see Comments]. Lancet 1989; 2: 227.
4. Collier DS, Calne RY, Pollard SG, Friend PJ, Thiru S. Rapamycin in experimental renal allografts in primates. Transplant Proc 1991; 23: 2246.
5. Kneteman NM, Lakey JR, Wagner T, Finegood D. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 1996; 61: 1206.
6. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc 1970; 2: 489.
7. Monaco AP, Gozzo JJ, Wood ML, Liegeois A. Use of low doses of homozygous allogeneic bone marrow cells to induce tolerance with antilymphocyte serum (ALS): tolerance by intraorgan injection. Transplant Proc 1971; 3: 680.
8. Wood ML, Monaco AP, Gozzo JJ, Liegeois A. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc 1971; 3: 676.
9. Caridis DT, Lieogeois A, Barret I, Lytle BW, Monaco AP. Survival of canine renal allografts after antilymphocytic serum and bone-marrow treatment. Br J Surg 1972; 59: 311.
10. Maki T, Gottschalk R, Wood ML, Monaco AP. Specific unresponsiveness to skin allografts in anti-lymphocyte serum-treated, marrow-injected mice: participation of donor marrow-derived suppressor T cells. J Immunol 1981; 127: 1433.
11. Hartner WC, De Fazio SR, Maki T, Markees TG, Monaco AP, Gozzo JJ. Prolongation of renal allograft survival in antilymphocyte-serum-treated dogs by postoperative injection of density-gradient-fractionated donor bone marrow. Transplantation 1986; 42: 593.
12. Thomas JM, Carver FM, Foil MB, et al. Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 1983; 36: 104.
13. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 51: 70.
14. Ricordi C, Karatzas T, Nery J, et al. High-dose bone marrow infusions to enhance allograft survival: the effect of timing. Transplantation 1997; 63: 7.
15. Wood ML, Gottschalk R, Monaco AP. The effect of cyclosporine on the induction of unresponsiveness in antilymphocyte serum-treated, marrow injected mice. Transplantation 1988; 46: 449.
16. Bobbio SA, Wood ML, Monaco AP. Significant augmentation of specific unresponsiveness by rapamycin in ALS-treated, bone marrow injected mice. Transpl Sci 1993; 3: 51.
17. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation 1997; 63(3): 359.
18. Billingham RE, Brent L, Medawar PB. The technique of free skin grafting in mammals. J Exp Biol 1951; 28: 385.
19. Monaco AP, Wood ML, Gray JG, Russell PS. Studies on heterologous antilymphocyte serum in mice: II. Effect on the immune response. J Immunol 1966; 96: 229.
20. Orosz CG, Horstemeyer B, Zinn NE, Bishop DK. Development and evaluation of a limiting dilution analysis technique that can discriminate in vivo alloactivated cytotoxic T lymphocytes from their naive CTL precursors. Transplantation 1989; 47: 189.
21. Wood ML, Orosz CG, Gottschalk R, Monaco AP. The effect of injection of donor bone marrow on the frequency of donor-reactive CTL in antilymphocyte serum-treated, grafted mice. Transplantation 1992; 54: 665.
22. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981; 126: 1614.
23. Otsu I, Gottschalk R, Monaco AP. Effect of graft inoculation with donor bone marrow cells on kidney allograft survival in antilymphocyte serum-treated rats. Transplant Proc 1994; 26: 3060.
24. Hartner WC, De Fazio SR, Markees TG, Maki T, Monaco AP, Gozzo JJ. Specific tolerance to canine renal allografts following treatment with fractionated bone marrow and antilymphocyte serum. Transplant Proc 1987; 19: 476.
25. Thomas FT, Carver FM, Foil MB, et al. Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression. Ann Surg 1983; 198; 370.
26. Barber WH, Diethelm AG, Laskow DA, Deierhoi MH, Julian BA, Curtis JJ. Use of cryopreserved donor bone marrow in cadaver kidney allograft recipients. Transplantation 1989; 47: 66.
27. Wood ML, Monaco AP. Adoptive transfer of specific unresponsiveness to skin allografts by spleen cells from ALS-treated, marrow-injected mice. Transplant Proc 1979; 11: 1023.
28. Wood ML, Gottschalk R, Monaco AP. Suppressor cells in specific unresponsiveness to skin allografts in thymectomized, ALS-treated, marrow-injected mice. Transplantation 1979; 28: 387.
29. Wood ML, Monaco AP. Suppressor cells in specific unresponsiveness to skin allografts in ALS-treated, marrow-injected mice. Transplantation 1980; 29: 196.
30. Maki T, Simpson M, Monaco AP. Development of suppressor T cells by antilymphocyte serum treatment in mice. Transplantation 1982; 34: 376.
31. Thomas JM, Carver FM, Cunningham P, Olsen L, Thomas FT. Veto cells induce long-term kidney allograft tolerance in primates without chronic immunosuppression. Transplant Proc 1991; 23: 11.
32. Carver M, Saldanha C, Matthews C, Sash C, Thomas J. In vitro suppression of alloreactivity by rhesus monkey bone marrow cells. Transplant Proc 1989; 21: 231.
33. Wood ML, Monaco AP. The effect of cyclophosphamide on the specific unresponsiveness to skin allografts induced in ALS-treated mice infused with donor bone marrow. J Immunol 1977; 118: 1456.
34. De Fazio SR, Plowey JM, Hartner WC, Gozzo JJ. Late adjunctive therapy with single doses of rapamycin in skin-allografted mice treated with antilymphocyte serum and donor bone marrow cells. Transplant Immunol 1996; 4(2): 105.
35. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6: 39.
36. Stepkowski SM, Kahan BD. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival. Transplant Proc 1991; 23: 3262.
37. Mohler KM, Streilein JW. Differential expression of helper versus effector activity in mice rendered neonatally tolerant of class II MHC antigens. Transplantation 1989; 47(4): 633.
38. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256.